In a report released today, Amit Dayal from H.C. Wainwright maintained a Buy rating on BioHarvest Sciences (BHST – Research Report), with a price target of $14.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amit Dayal has given his Buy rating due to a combination of factors that highlight BioHarvest Sciences’ strong financial performance and growth prospects. The company reported a significant year-over-year increase in revenue and gross profit for the first quarter of 2025, demonstrating its ability to enhance margins and grow its customer base. The management’s expectation of continued revenue growth, driven by an expanding product lineup and increased production efficiency, further supports this positive outlook.
Additionally, BioHarvest’s strategic initiatives in its CDMO business, including the development of new molecules and partnerships, are seen as potential catalysts for future growth. The company’s vertically integrated model and innovative use of AI in various operations position it uniquely in the market, allowing it to maintain high margins and competitive advantage. The projected long-term revenue growth and positive EBITDA outlook also contribute to the Buy rating, with a price target derived from a discounted cash flow analysis that accounts for execution risks.
In another report released on May 16, Craig-Hallum also reiterated a Buy rating on the stock with a $15.00 price target.